Dementia with Lewy Bodies¶
Chapter 445 | Part 13: Neurologic Disorders
KEY CLINICAL POINTS¶
- Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia after Alzheimer’s disease, with an incidence of ~7 per 100,000 person-years.
- DLB is characterized by fluctuating cognition, visual hallucinations, rapid eye movement sleep behavior disorder (RBD), and parkinsonism, often with early autonomic dysfunction.
- Key diagnostic biomarkers include reduced CSF α -synuclein, amyloid PET abnormalities, and dopamine transporter (DAT) scan deficits in the basal ganglia.
- Cholinesterase inhibitors (donepezil, rivastigmine) are first-line treatments for mild-to-moderate DLB, while memantine may be used for moderate-to-severe cases.
- DLB frequently co-occurs with Alzheimer’s disease pathology, complicating differential diagnosis and prognosis.
1. DEFINITION & OVERVIEW¶
Dementia with Lewy bodies (DLB) is a synucleinopathy characterized by the accumulation of α -synuclein aggregates (Lewy bodies) in the brain. It presents as a neurodegenerative dementia with prominent cognitive decline, parkinsonism, and fluctuating cognition. DLB is distinct from Alzheimer’s disease and Parkinson’s disease dementia (PDD) but shares overlapping features.
Table 445-1 Distinguishing MCI Due to Lewy Body Disease or Alzheimer’s Disease¶
| CLINICAL FEATURES | PRODROMAL MCI-LB PATHOLOGY | PRODROMAL MCI-AD PATHOLOGY |
|---|---|---|
| MCI | MCI usually affecting executive, attention, and/or visuospatial functions | MCI with impaired memory and semantic naming |
| Fluctuating cognition | Frequent and severe | Rare or not severe |
| Sleep | REM sleep behavior disorder | Insomnia, frequent awakenings |
| Visual hallucinations | Frequent | |
| Biomarkers | Decreased CSF a-synuclein by RT-QuIC | Decreased CSF b-amyloid |
Table 445-1 (Continued) Biomarkers and Imaging¶
| Biomarkers | PRODROMAL MCI-LB PATHOLOGY | PRODROMAL MCI-AD PATHOLOGY |
|---|---|---|
| Polysomnogram | REM sleep behavior disorder without atonia | Normal |
| MRI | Atrophy of the amygdala | Atrophy of the parahippocampal/hippocampal areas |
| Biomarkers | PRODROMAL MCI-LB PATHOLOGY | PRODROMAL MCI-AD PATHOLOGY |
|---|---|---|
| Amyloid PET scan | Normal, unless associated with AD | Abnormal parietotemporal areas |
| DAT scan or PET dopamine scan | Reduced dopamine transporter in the basal ganglia, particularly putamen | Normal |
1.1 Clinical Spectrum¶
DLB exists on a spectrum with Parkinson’s disease dementia (PDD) and may co-occur with Alzheimer’s disease pathology. Approximately 10% of Parkinson’s disease patients develop PDD annually, while DLB incidence is ~7 per 100,000 person-years. Both conditions are more prevalent in older adults and affect men more frequently.
1.2 Diagnostic Criteria¶
Formal criteria identify three stages of progression: (1) brainstem predominant; (2) transitional limbic; and (3) diffuse neocortical. Diagnosis relies on clinical features, biomarkers, and exclusion of other dementias.
2. EPIDEMIOLOGY¶
DLB is the second most common cause of neurodegenerative dementia after Alzheimer’s disease. Incidence is ~7 per 100,000 person-years, with prevalence increasing with age. Both DLB and Parkinson’s disease dementia (PDD) affect men more frequently than women. Genetic factors may contribute to rare hereditary forms like CADASIL or cerebral amyloid angiopathy.
2.1 Risk Factors¶
Age is the primary risk factor, with prevalence increasing significantly after 65 years. Other risk factors include family history of early-onset dementia, vascular risk factors (hypertension, diabetes, dyslipidemia), and prior stroke history.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
DLB is a synucleinopathy caused by abnormal accumulation of α -synuclein aggregates (Lewy bodies) in neurons and glia. These aggregates disrupt synaptic function and lead to neurodegeneration. Pathogenesis involves prion-like propagation of misfolded α -synuclein through neural pathways, starting in the enteric nervous system and spreading to the brainstem, limbic system, and cortex.
3.1 Molecular Mechanisms¶
Lewy bodies contain α -synuclein, ubiquitin, and phosphorylated neurofilaments. The presence of α -synuclein aggregates classifies DLB as a synucleinopathy. Neuronal loss and synaptic dysfunction, rather than Lewy bodies themselves, best predict clinical deficits.
4. CLINICAL FEATURES¶
DLB presents with fluctuating cognition, visual hallucinations, RBD, parkinsonism, and autonomic dysfunction. Cognitive decline affects executive function, attention, and visuospatial skills more than memory. Early symptoms may include delirium, syncope, and erectile dysfunction. Patients are highly sensitive to infections and metabolic disturbances.
4.1 Prodromal Phase¶
Prodromal DLB includes mild cognitive impairment (MCI) with executive dysfunction, RBD, and parkinsonism. RBD may precede dementia by years and is a hallmark feature. Early anosmia, constipation, and depression are also common.
5. DIFFERENTIAL DIAGNOSIS¶
DLB must be differentiated from Alzheimer’s disease, Parkinson’s disease dementia, vascular dementia, and multiple system atrophy (MSA). Key distinguishing features include fluctuating cognition, visual hallucinations, RBD, and DAT scan abnormalities. Amyloid PET and CSF biomarkers aid differentiation.
5.1 Key Differentiators¶
DLB vs. Alzheimer’s: Fluctuating cognition, visual hallucinations, and RBD are more prominent in DLB. DLB vs. MSA: MSA shows more severe autonomic dysfunction and preserved cognition. DLB vs. PDD: PDD develops in long-standing Parkinson’s disease, while DLB dementia precedes parkinsonism.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires MRI to detect white matter hyperintensities, microbleeds, and infarcts. Biomarkers include CSF α -synuclein (reduced), amyloid PET (normal unless coexisting AD), and DAT scan (reduced dopamine transporter). Polysomnography confirms RBD. Genetic testing for CADASIL or cerebral amyloid angiopathy is considered in young-onset cases.
6.1 Diagnostic Algorithms¶
- MRI with FLAIR/T2* sequences to detect vascular lesions. 2. CSF analysis for α -synuclein and amyloid. 3. DAT scan to assess dopamine transporter deficits. 4. Polysomnography for RBD confirmation. 5. Amyloid PET to exclude coexisting AD pathology.
7. MANAGEMENT & TREATMENT¶
Cholinesterase inhibitors (donepezil, rivastigmine) are first-line for mild-to-moderate DLB. Memantine may be used for moderate-to-severe cases. Non-pharmacologic management includes physical therapy for mobility, sleep hygiene for RBD, and caregiver support. Antipsychotics should be used cautiously due to risk of worsening dementia.
7.1 Treatment Algorithm¶
- Start cholinesterase inhibitors for mild-to-moderate cognitive impairment. 2. Use high-dose donepezil or memantine for moderate-to-severe dementia. 3. Manage RBD with clonazepam or melatonin. 4. Address autonomic symptoms with lifestyle modifications and medications. 5. Avoid antipsychotics unless necessary, due to risk of neuroleptic malignant syndrome.
8. PROGNOSIS & COMPLICATIONS¶
DLB has a variable prognosis, with progressive cognitive decline and increased risk of falls, syncope, and infections. Complications include severe autonomic dysfunction, motor fluctuations, and psychiatric symptoms. Mortality is higher than in Alzheimer’s disease due to complications of advanced disease.
8.1 Prognostic Factors¶
Early onset, severe cognitive impairment, and coexisting AD pathology are associated with poorer outcomes. Patients with DLB are more likely to develop severe autonomic dysfunction and require institutional care.
9. SPECIAL CONSIDERATIONS¶
DLB requires careful management in elderly patients due to increased fall risk and medication sensitivity. Antipsychotics should be avoided unless absolutely necessary. In younger patients, genetic testing for CADASIL or cerebral amyloid angiopathy may be warranted. Caregiver education is critical due to behavioral symptoms and fluctuating cognition.
9.1 Pregnancy & Pediatrics¶
No specific guidelines for pregnancy; cholinesterase inhibitors are generally considered safe but should be used with caution. DLB is rare in children, but α -synucleinopathies may present in young adults with atypical features.
10. KEY POINTS & CLINICAL PEARLS¶
DLB is a synucleinopathy with Lewy bodies in the brainstem and cortex. Key features include fluctuating cognition, visual hallucinations, RBD, and parkinsonism. Early diagnosis relies on biomarkers (CSF α -synuclein, DAT scan) and exclusion of other dementias. Cholinesterase inhibitors are first-line, while antipsychotics should be used cautiously. DLB frequently co-occurs with Alzheimer’s disease pathology, complicating management.